Tamoxifen (tamoxifen citrate) is a selective oestrogen receptor modulator (SERM), used in selected breast-cancer treatment and risk reduction. NCI medicine identity.
Confidence is high in the identity and need for receptor, clot-risk and interaction checks. Care descriptions below are attributed guidance. This review does not establish independently finance-cleared superiority or provide an individual prescription.
- Treatment of diagnosed cancer, DCIS risk reduction and prevention without cancer are different settings.
- Report clot symptoms, unusual vaginal bleeding, severe skin reactions and heart-rhythm concerns promptly.
- Antidepressants, anticoagulants and other hormonal treatments require specific interaction review.
- Pregnancy and breastfeeding precautions extend beyond assumptions about periods or menopause.
- England community prescription items describe use, not individual benefit or global popularity.
Table of contents
- Evidence summary
- What tamoxifen is: names, receptors and formulations
- How receptor blocking and CYP2D6 activation work
- Breast cancer, DCIS and prevention: different purposes
- Managing symptoms, bone health and supplement claims
- What England prescribing counts and IBIS-I establish
- Clots, bleeding, skin reactions and emergency symptoms
- Antidepressants, anticoagulants, hormones and QT risk
- Pregnancy, breastfeeding, surgery and suitability
- Taking tamoxifen, missed doses and excess tablets
- Animal evidence and funding behind the medicine
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Receptors and indications | NCI care and UK scope. | Trial receipts unclosed; commercial label. | Different purposes; no comparative benefit. |
| Clot, womb and rhythm safety | Provider, NHS triage and current packet. | Separate provider/public finance; seller interests. | Urgent assessment; no personal monitoring regimen. |
| CYP2D6 interactions | Dated MHRA activation precaution. | Industry-fee/public regulator routes. | Medicine review, not a mortality/genotyping algorithm. |
| IBIS-I prevention trial | Original randomized long-term report. | AZ drug supply and author ties; public/charity grants. | Tier 4/D; outcomes excluded. |
| English use volume | FY2025/26 chemical-substance row. | Agency finance independently traced. | Prescription items, not global or indication-specific popularity. |
| Complementary products | Dated cancer-care safety education. | NCCIH public/gift routes; personal chain unclosed. | No established tamoxifen-adjunct benefit here. |
What tamoxifen is: names, receptors and formulations
NCI lists Soltamox as a US brand. Names and geography.
ER and PR mean oestrogen and progesterone receptors. Tissue from biopsy or surgery identifies hormone-receptor status; HER2 is a different marker. Receptors can change, so selected recurrent disease needs reassessment. Pathology distinctions.
Keep the actual pathology result and prescribed product together when discussing care. A generic name does not specify the tablet strength, formulation or every inactive ingredient. A brand mentioned here is an example, not an authenticity certification, supply guarantee or preferred manufacturer.
How receptor blocking and CYP2D6 activation work
Tamoxifen binds oestrogen receptors, blocking breast-tissue oestrogen effects while acting differently in other tissues. Receptor mechanism.
The liver enzyme CYP2D6 helps produce endoxifen, an active metabolite. Strong enzyme inhibitors can reduce active-metabolite exposure. Activation and interaction mechanism.
A receptor effect, laboratory concentration and a patient’s eventual outcome are different findings. Mechanism alone cannot quantify recurrence, survival or a personal risk of harm. This guide provides no genetic-test algorithm, endoxifen target or medicine-adjustment formula.
Breast cancer, DCIS and prevention: different purposes
US uses include advanced breast cancer in men and women, selected adjuvant care in women, and risk reduction after local therapy for ductal carcinoma in situ (DCIS). US treatment contexts.
Tamoxifen is used before or after menopause; men receiving adjuvant treatment for early ER-positive breast cancer usually start with it. Endocrine care can address adjuvant, recurrent or advanced disease. Specialist care settings.
UK Nolvadex lists moderate/high-risk prevention and anovulatory infertility. UK indication boundary.
Clarify whether the prescription concerns prevention or diagnosed disease. Different purposes. Ask the responsible service to record the review and breast-surveillance plan.
Managing symptoms, bone health and supplement claims
The Christie describes hot flushes, nausea, joint symptoms, mood changes and vaginal dryness. Layered clothing and nonhormonal moisturisers/lubricants may help comfort; persistent difficulties need review. Check before taking menopause products or herbal remedies. Dated practical care advice.
Report new blurred vision or other sight changes to the team. Eye-symptom review.
Before menopause, discuss bone health: density can decrease. Menopause-specific bone precaution. No universal bone protection is assumed.
Discuss complementary products with the cancer team; they should not replace or delay care. This safety principle does not establish that a supplement improves tamoxifen outcomes. Complementary-care limits.
Keep the actual ingredient list for the pharmacist. A product described as “natural” or marketed for hormones still needs review. Comfort measures and managing a documented deficiency have different purposes from treating cancer or changing drug activation.
What England prescribing counts and IBIS-I establish
The original FY2025/26 England chemical-substance workbook records 491,074 tamoxifen-citrate prescription items, BNF code 0803041S0. Actual row 1026.
PCA covers community dispensing in England. Release scope.
Hospital-issued prescriptions dispensed in the community are included; hospital dispensary supplies, private and prison dispensing are excluded. The indication is not recorded. Original coverage limits. Items are not unique patients, swallowed doses or worldwide use.
IBIS-I randomized higher-risk women to tamoxifen or matching placebo. Its original long-term report names public/charity grants, AstraZeneca tablet supply and author relationships. Outcomes are excluded from the independent verdict. Original design and finance.
Prescribing volume cannot identify the best medicine for a particular cancer. It also cannot separate prevention from treatment or prove an independently established benefit. No brand ranking, recurrence percentage or survival estimate is supplied.
Clots, bleeding, skin reactions and emergency symptoms
DVT means deep vein thrombosis, a clot in a deep vein. New pain or swelling in one leg needs urgent assessment. In the UK seek an urgent GP appointment or NHS 111 advice. Suspected leg-clot action.
Pulmonary embolism means a clot blocking a lung blood vessel. Call 999 or the local emergency number for severe breathing difficulty, chest/upper-back pain, a very fast heartbeat or collapse. Do not drive yourself. Emergency assessment.
Sudden facial droop, arm weakness or speech difficulty requires emergency help even if symptoms stop. Stroke signs.
Sudden mouth/throat swelling, difficult breathing or collapse can be anaphylaxis: call emergency services. Severe allergic symptoms.
Stop Nolvadex; seek immediate help for blistering, peeling or mouth/eye ulcers. Serious skin warning.
Report unusual vaginal bleeding, discharge or pelvic pain promptly, including after treatment; uterine cancer is possible. Womb warning.
For an acute reaction, obtain urgent care and advice on further doses. Do not wait for the routine oncology appointment or assume a new symptom is harmless because it appears on a side-effect list.
Antidepressants, anticoagulants, hormones and QT risk
The dated MHRA precaution identifies strong CYP2D6 inhibitors including paroxetine, fluoxetine, bupropion, quinidine and cinacalcet. Review alternatives with the prescriber rather than stopping another medicine yourself. Interaction caution.
Prevention excludes previous DVT/PE or required coumarins; cancer treatment needs individual anticoagulant review. Do not co-use anastrozole. Indication-specific restrictions.
Tamoxifen may prolong QT, altering heart electrical timing; the UK label recommends ECG and electrolyte checks for relevant risks. Heart-rhythm precaution.
Review all medicines, including nonprescription products, before tamoxifen. Complete medicine-list review.
Disclose HRT, hormonal contraception and other endocrine medicines. Hormonal-product review.
A planned switch from tamoxifen to another endocrine medicine differs from combining tablets yourself. Interaction concern should trigger coordinated review; this article does not choose an alternative antidepressant, anticoagulant or anticancer agent.
Pregnancy, breastfeeding, surgery and suitability
Nolvadex is contraindicated during pregnancy; possible pregnancy needs immediate contact. Breastfeeding is not recommended. Confirm nonhormonal contraception and post-treatment precautions. Pregnancy and feeding precautions.
Discuss surgery-related interruption decisions with both teams; the indication matters. Procedure-related review.
Tell the clinician about any previous blood clot. Clot-history disclosure.
This guide gives no conception date, feeding clearance or elective-surgery stopping interval. Do not rely on an old handout, an absent period or someone else’s course to settle these decisions. An emergency symptom needs urgent assessment rather than a planned treatment-break discussion.
Taking tamoxifen, missed doses and excess tablets
For Nolvadex, skip a forgotten dose if the next is near; otherwise take when remembered. Never double doses. Missed-dose instruction.
After excess tablets, contact a doctor or pharmacist immediately, even without symptoms. Excess-dose action.
The Christie describes tablets taken with or without food. Administration context. Confirm instructions for the actual formulation rather than converting tablet strength into a liquid volume yourself.
Troublesome side effects need specialist review of possible treatment changes. Clinician-led options.
At dispensing, confirm the product, strength and responsible prescriber. Keep the packet available for urgent assessment. This guide provides no starting dose, escalation, fertility-cycle regimen, anticancer combination or fixed multi-year course.
Animal evidence and funding behind the medicine
Animal findings do not clear human pregnancy safety. Animal-data boundary.
AstraZeneca’s 2025 financial statements disclose product, alliance and collaboration revenue plus borrowing channels. Selected financial originals Filings report control through AstraZeneca Intermediate Holdings to AstraZeneca PLC. Immediate parent Reported parent.
IBIS-I reports free AstraZeneca study tablets and relevant author relationships. Its funder non-involvement statement does not erase those interests. Financial disclosure.
This traces one current UK holder, not every generic or brand worldwide. Seller information is used for identified safety/licensing roles; commercially supported trial outcomes remain excluded from an independent efficacy verdict. Government or charity involvement does not itself clear all author and trial finances.
Funding and source roles
Research funding at a glance
29 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI: tamoxifen citrate | Separate appropriations/gifts below; no named medical byline or complete page/reviewer/trial receipts verified. | United States; NCI, Bethesda, Maryland. | Tier 2 educational context, provisional. | C, provisional — 2 January 2025. Clinical responsibility favors accuracy; original efficacy finances remain unclosed. |
| NCI: breast endocrine treatment | Separate appropriations/gifts below; no named medical byline or complete page/reviewer/trial receipts verified. | United States; NCI, Bethesda, Maryland. | Tier 2 educational context, provisional. | C, provisional — 23 September 2026. Clinical responsibility favors accuracy; original efficacy finances remain unclosed. |
| NCI: breast biomarker tests | Separate appropriations/gifts below; no named medical byline or complete page/reviewer/trial receipts verified. | United States; NCI, Bethesda, Maryland. | Tier 2 educational context, provisional. | C, provisional — 2 December 2025. Clinical responsibility favors accuracy; original efficacy finances remain unclosed. |
| AstraZeneca: Nolvadex UK SmPC | Commercial holder; parent/revenue routes separately traced below. | United Kingdom; AstraZeneca UK, Cambridge. | Tier 4 seller material; efficacy excluded. | D for independence — text 22 May 2026; emc 2 June. Seller safety duties; outcomes excluded. |
| Nolvadex patient leaflet | Commercial AstraZeneca; receipts unclosed, records below. | United Kingdom. | Tier 4 seller. | D — March 2026, emc 29 May. Regulated safety duties; commercial bias; efficacy excluded. |
| The Christie: tamoxifen care leaflet | Trust-specific accounts below; leaflet authors, individual interests and source-trial receipts unclosed. | United Kingdom; Manchester. | Tier 2 provider context, provisional. | C, provisional — April 2023; April 2026 deadline passed. Care accountability; older bleeding reassurance, contraceptive interval and universal monitoring advice excluded. |
| The Christie: 2025/26 accounts | NHS commissioner contracts; other/non-NHS activity; R&D, education/services, charity contributions, commercial income and rentals separately recorded. | United Kingdom; NHS foundation trust, Manchester. | Tier 3 institutional financial report. | B, provisional — actual 140-page original, selected notes 1.2/1.9/3 read. Audit supports tracing; every sponsor, clinician and leaflet allocation unclosed. |
| The Christie: report index and address | Same trust; money routes independently documented in its accounts, not inferred from national NHS policy. | United Kingdom; Wilmslow Road, Manchester M20 4BX. | Tier 3 institutional identity self-report. | B, provisional — actual current body/footer read. Public identity accountability; not a medical source or allocation audit. |
| MHRA: tamoxifen and CYP2D6 | Industry-fee/public institutional routes below; alert-specific author and underlying-study receipts unclosed. | United Kingdom; MHRA. | Tier 3 regulatory context with industry-fee route. | C, provisional — November 2010 article, posted 11 December 2014. Safety accountability; numeric mortality and old genotyping position not transferred as current advice. |
| NHS: deep vein thrombosis | National policy below; individual page/reviewer and original-study payments unclosed. | United Kingdom; national website. | Tier 2 clinical safety context, provisional. | C, provisional — 30 April 2026. Clinical accountability supports triage; no tamoxifen-event incidence or efficacy inference. |
| NHS: pulmonary embolism | National policy below; individual page/reviewer and original-study payments unclosed. | United Kingdom; national website. | Tier 2 clinical safety context, provisional. | C, provisional — 25 May 2023; 2026 review deadline passed. Clinical accountability supports triage; no tamoxifen-event incidence or efficacy inference. |
| NHS: stroke symptoms | National policy below; individual page/reviewer and original-study payments unclosed. | United Kingdom; national website. | Tier 2 clinical safety context, provisional. | C, provisional — 12 September 2024. Clinical accountability supports triage; no tamoxifen-event incidence or efficacy inference. |
| NHS: anaphylaxis | National policy below; individual page/reviewer and original-study payments unclosed. | United Kingdom; national website. | Tier 2 clinical safety context, provisional. | C, provisional — 21 June 2023; 2026 review deadline passed. Clinical accountability supports triage; no tamoxifen-event incidence or efficacy inference. |
| IBIS-I: original long-term follow-up | CRUK grant C569/A16891; Australian NHMRC project grants; AstraZeneca supplied active/placebo tablets. Cuzick/Forbes other-trial AZ funding; Cuzick consulting. | United Kingdom and Australia funding; eight-country trial. Every funder HQ and ultimate donor unverified. | Tier 4 commercially supported project; outcomes excluded. | D for independence — online December 2014, print January 2015. Actual original methods/funding/COI read. Reported funder non-involvement does not erase drug supply or author ties. |
| NCCIH: complementary cancer care | Public/gift originals below; credited White, Olaku, King, Sansevere and Shurtleff personal/page interests unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 2 educational safety context, provisional. | C, provisional — October 2021. Public clinical duties; no tamoxifen-adjunct benefit or blanket supplement safety established. |
| AstraZeneca: 2025 financial statements | Medicine product sales; separate alliance profit/revenue/royalty receipts and collaboration licensing/milestones. Bonds, bank facilities and leases are financing routes. | United Kingdom; multinational AstraZeneca group. | Tier 4 seller financial report; financial-only. | D for independence — actual 79-page original, selected revenue/borrowing notes read. Accounting scrutiny supports money tracing; product-specific receipts/backers unclosed. |
| AstraZeneca UK: reported control | AstraZeneca Intermediate Holdings Ltd: at least 75% share/voting control and director-appointment rights, notified 6 April 2016. | England company 03674842; Cambridge registered address. | Tier 3 company-filed control disclosure, provisional. | C, provisional — actual current PSC body read. Legal disclosure incentives; registry does not verify filed accuracy or all beneficial interests. |
| AstraZeneca intermediate parent: control | AstraZeneca PLC: at least 75% share/voting control and director-appointment rights; no precise stake or full shareholder ledger inferred. | England company 06442028; Cambridge registered address. | Tier 3 company-filed control disclosure, provisional. | C, provisional — actual current PSC body read. Statutory disclosure favors accuracy; no trial/page allocation or every investor traced. |
| NCI: enacted budget | Congressional appropriations through NIH/HHS; enacted fiscal funding distinguished from forward requests. | United States; federal NCI, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — updated 14 May 2026, actual body read. Public budget scrutiny supports accuracy; complete page and trial allocations unclosed. |
| NCI: Gift Fund and address | Voluntary Gift Fund contributions and Breast Cancer Research Stamp route; research designations/company-name field do not establish named page sponsorship. | United States; 9000 Rockville Pike, Bethesda, Maryland 20892. | Tier 3 institutional financial self-report. | B, provisional — 27 August 2025, actual body read. Disclosure/accountability support money tracing; accepted donor receipts and allocation unclosed. |
| NHSBSA: England PCA 2025/26 | Separate agency accounts below; PCA staff/page allocation unclosed. | United Kingdom; England community dispensing. | Tier 2 administrative statistics, provisional. | B, provisional — 4 June 2026. Reimbursement/statistical accountability; no clinical indication or efficacy inference. |
| NHSBSA: original chemical workbook | Same separately documented agency routes; supplier sponsorship not inferred. | United Kingdom; England. | Tier 2 administrative data, provisional. | B, provisional — actual Chemical_Substances row 1026 checked. Items are not patients, doses, adherence, OTC or worldwide use. |
| NHSBSA: PCA methodology | Same documented agency routes; analytic contracts unclosed. | United Kingdom; England. | Tier 2 methods disclosure, provisional. | B, provisional — June 2026 scope/limitations selected. Administrative checking favors totals; no cancer-specific indication ranking established. |
| NHSBSA: accounts 2025/26 | Parliamentary DHSC funding; separate full-cost service charges/public repayment work and DHSC student support. NHS SBS investment noted; complete co-ownership unclosed. | United Kingdom; Stella House, Goldcrest Way, Newburn Riverside, Newcastle upon Tyne NE15 8NY. | Tier 3 institutional financial report. | B, provisional — actual 163-page original, selected pages 132–133/143 and address read. Statutory accounting aids reliability; PCA staff/page allocations remain unassigned. |
| NHS national content/funding policy | DHSC funding; no advertising/corporate sponsorship. Staff/external contributors must disclose interests; full named receipts are not published here. | United Kingdom; national website, separate from provider trusts. | Tier 3 financial/editorial self-report. | B, provisional — 14 October 2022; October 2025 review deadline passed. Public accountability favors accuracy; policy is not current provider accounts or trial clearance. |
| MHRA: accounts 2025/26 | Most running costs from statutory industry fees/non-statutory goods/services; separate DHSC funding. Conflict safeguards described; no alert-specific payer assigned. | United Kingdom; DHSC executive agency. | Tier 3 institutional financial report. | B, provisional — actual 186-page original, funding section and financial statements selected. Statutory audit supports money tracing; regulated-industry and access incentives remain. |
| MHRA: official contact/identity | Industry/public routes documented in separate accounts; complete board/contractor interests unclosed. | United Kingdom; 10 South Colonnade, London E14 4PU. | Tier 3 institutional identity self-report. | B, provisional — actual government contact body read. Official address is reliable identity evidence, not proof of independent efficacy. |
| NCCIH: appropriations history | Enacted congressional appropriations reported through FY2024; no FY2026 request treated as enacted or page allocation inferred. | United States; 9000 Rockville Pike, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual dated fiscal entries read. Public budget scrutiny favors accuracy; complete current receipts and disease-page allocation unclosed. |
| NCCIH: separate Gift Fund route | Authorized voluntary donations/bequests; conditional research-area or unconditional gifts separate from appropriations. Accepted donor receipts unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual authority/process read. Disclosure and public accountability favor accuracy; permitted gifts do not establish corporate payment for the safety page. |
Frequently asked questions
Is tamoxifen the same as letrozole or anastrozole? No. Tamoxifen modulates receptors; aromatase inhibitors reduce oestrogen production. Changes require a specialist plan. Different endocrine classes.
Does prevention mean I already have cancer? No. Risk reduction is a separate decision requiring clinical review.
What if I take an antidepressant or blood thinner? Have the exact medicines reviewed together. Do not stop or replace another prescribed treatment yourself.
Do the English prescribing figures show the best brand? No. Item counts do not measure brand quality, patient outcomes, clinical indication or worldwide popularity.
Sources and funding notes
Source roles are geographically and clinically bounded. Current UK product warnings are used without personal doses or monitoring calendars. The Christie’s April 2026 review deadline, and the dated NHS pulmonary-embolism/anaphylaxis/policy deadlines, have passed; only specified contextual advice is used. IBIS-I’s original methods, acknowledgments and declarations were read; maker tablet supply is included, not hidden behind its public/charity grants. Full original trial efficacy financing for all uses, page payments and complete reviewer interests remain unclosed. Institutional accounts establish money routes, not clinical independence. No guaranteed prevention, cure, independent superiority, brand preference or universal conception/surgery/treatment timetable is supplied.
- NCI: tamoxifen citrate — Identity and US use contexts.
- NCI: breast endocrine treatment — Receptor mechanism, menopause and specialist care.
- NCI: breast biomarker tests — Tissue receptors versus HER2.
- AstraZeneca: Nolvadex UK SmPC — Indication-specific safety and preclinical boundary.
- Nolvadex patient leaflet — Pregnancy, dose errors and urgent warnings.
- The Christie: tamoxifen care leaflet — Selected symptoms, comfort measures and clinical review.
- The Christie: 2025/26 accounts — Selected institutional revenue channels only.
- The Christie: report index and address — Current report link and institutional location.
- MHRA: tamoxifen and CYP2D6 — Dated activation/interaction precaution only.
- NHS: deep vein thrombosis — Suspected leg-clot urgent assessment.
- NHS: pulmonary embolism — Severe breathing/chest/collapse emergency triage.
- NHS: stroke symptoms — FAST emergency signs, including symptoms that stop.
- NHS: anaphylaxis — Airway swelling/breathing/collapse emergency action.
- IBIS-I: original long-term follow-up — Randomized prevention design and financial disclosures only.
- NCCIH: complementary cancer care — Disclosure and non-replacement safety only.
- AstraZeneca: 2025 financial statements — Company revenue/financing routes only.
- AstraZeneca UK: reported control — Immediate reported parent, not exact ownership.
- AstraZeneca intermediate parent: control — Reported ultimate corporate control band.
- NCI: enacted budget — Institutional appropriations, not drug-page funding.
- NCI: Gift Fund and address — Separate gift authority/routes only.
- NHSBSA: England PCA 2025/26 — Publication and community setting.
- NHSBSA: original chemical workbook — Tamoxifen-citrate item count/code only.
- NHSBSA: PCA methodology — Community dispensing, hospital-issued prescription and indication limits.
- NHSBSA: accounts 2025/26 — Institutional funding/HQ trace only.
- NHS national content/funding policy — Website funding and editorial safeguards only.
- MHRA: accounts 2025/26 — Regulator-specific funding only.
- MHRA: official contact/identity — Jurisdiction and office only.
- NCCIH: appropriations history — Congressional route and institutional address only.
- NCCIH: separate Gift Fund route — Gift authority, not a named page sponsor.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.